Answers are grounded in this paper and cite their sources.
Pretransplant malignancy is associated with increased risk of all cause-mortality, cancer-specific mortality and of developing de novo malignancies after transplantation compared with those without PTM. These results reaffirm the need for careful selection of transplant recipients with PTM. Tailored screening and management strategies should be developed for this group of patients.
No takes yet. Share an insight, caveat, or question.
Acuña et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: